- Home
- GTBP vs QNCX Comparison
GTBP vs QNCX Comparison
Compare GTBP & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTBP | QNCX |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 17.1M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GTBP | QNCX |
|---|---|---|
| Price | $0.38 | $19.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 168.7K |
| Earning Date | 05-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.75 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.08 |
| 52 Week High | $2.29 | $20.72 |
Technical Indicators
Market Signals| Indicator | GTBP | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 83.28 |
| Support Level | $0.29 | $0.89 |
| Resistance Level | $0.46 | $19.26 |
| Average True Range (ATR) | 0.05 | 1.46 |
| MACD | -0.01 | 0.51 |
| Stochastic Oscillator | 27.16 | 88.88 |
Price Performance
Historical ComparisonAbout GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.